07:33 AM EST, 01/02/2025 (MT Newswires) -- Neumora Therapeutics ( NMRA ) said Thursday that the phase 3 KOASTAL-1 study of navacaprant in treating major depressive disorder failed to meet its primary endpoint.

The company said the study failed to demonstrate a statistically significant reduction in depressive symptoms as measured by Montgomery-Asberg Depression Rating Scale total score at week six compared with placebo.

The study also failed to achieve the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale, Neumora added.

KOASTAL-1 is the first of three replicate phase 3 studies designed to evaluate the efficacy and safety of navacaprant in adult patients with moderate to severe major depressive disorder. The company said it plans further analysis of the results and expects to release additional updates on Jan. 14.

Neumora shares fell more than 75% in premarket trading.